AstraZeneca
This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Study D9890C00001 (Lumi-NHL) is a modular study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-NHL. Module 1 aims to study AZD4512 monotherapy with participants in R/R B-NHL who have been exposed to at least 2 prior lines of therapy. Module 2 aims to study AZD4512 in combination with surovatamig in participants with relapsed or refractory LBCL.
Core Inclusion Criteria * Eligible patients must be adults (≥18 years) * Additional criteria include measurable disease by Lugano 2014, ECOG performance status ≤2, and adequate organ and bone marrow function (as specified by blood counts, cardiac ejection fraction, renal and hepatic parameters, and coagulation indices). Module 1 Monotherapy Inclusion criteria * Documented histologically confirmed diagnosis of B-cell non-Hodgkin lymphoma (B-NHL) as per World Health Organization (WHO) 2022 classification. In the dose escalation phase, any B-NHL subtype is allowed (excluding some subtypes), wh…
AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion
Surovatamig (AZD0486) is a 'bispecific' antibody to be administered via IV infusion